Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial

BACKGROUND: Daily methadone maintenance or buprenorphine treatment is the standard-of-care (SoC) medication for opioid use disorder (OUD). Subcutaneously injected, extended-release buprenorphine (BUP-XR) may be more effective—but there has been no superiority evaluation. METHODS: This pragmatic, par...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsden, John, Kelleher, Mike, Gilvarry, Eilish, Mitcheson, Luke, Bisla, Jatinder, Cape, Angela, Cowden, Fiona, Day, Edward, Dewhurst, Jonathan, Evans, Rachel, Hardy, Will, Hearn, Andrea, Kelly, Joanna, Lowry, Natalie, McCusker, Martin, Murphy, Caroline, Murray, Robert, Myton, Tracey, Quarshie, Sophie, Vanderwaal, Rob, Wareham, April, Hughes, Dyfrig, Hoare, Zoë
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692661/
https://www.ncbi.nlm.nih.gov/pubmed/38045803
http://dx.doi.org/10.1016/j.eclinm.2023.102311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692661/
https://www.ncbi.nlm.nih.gov/pubmed/38045803
http://dx.doi.org/10.1016/j.eclinm.2023.102311

Ejemplares similares